Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Colon Cancer
  •  Brain and Spinal Cord Cancer
  •  Urological Cancers
  •  Hormone Therapy
  •  Prostate Cancer
  •  Targeted Therapy
  •  Ovarian Cancer
  •  Bladder Cancer

Abstract

Citation: Clin Oncol. 2016;1(1):1072.DOI: 10.25107/2474-1663.1072

Misdiagnosing Hepatic Inflammatory Pseudotumor as Hepatocellular Carcinoma: A Case Report

Lei Y, Bin Z, Ying-he Q, Ning-jia S, Xin-yuan L, Wan Yee L, LAI, Eric CH, Yong-jie Z


Second Department of Biliary Surgery, Eastern Hepatobiliary Surgery Hospital, China
Department of Pathology, Eastern Hepatobiliary Surgery Hospital, China
The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong

*Correspondance to: Zhang, Yong-jie 

 PDF  Full Text Case Report | Open Access

Abstract:

A 61-year-old Chinese male was found to have a lesion in the left liver on routine body check-up. Laboratory tests revealed no abnormalities except for a rise in C-reactive protein (CRP). Computed tomography (CT) showed features suggestive of hepatocellular carcinoma (HCC). The patient underwent liver IVb segmentectomy and cholecystectomy. Histopathology showed features of hepatic inflammatory pseudotumor. The CRP decreased to close to normal on postoperative day 9. The patient was discharged home well on postoperative day 11.

Keywords:

Hepatic inflammatory pseudotumor; Hepatocellular carcinoma; Hepatectomy; Cholecystectomy

Cite the Article:

Lei Y, Bin Z, Ying-he Q, Ning-jia S, Xinyuan L, Wan Yee L, et al. Misdiagnosing Hepatic Inflammatory Pseudotumor as Hepatocellular Carcinoma: A Case Report. Clin Oncol. 2016; 1: 1072.

Search Our Journal

Journal Indexed In

Articles in PubMed

Metastatic Retroperitoneal Paraganglioma: Case Report and Review of the Literature
 PubMed  PMC  PDF  Full Text
LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Erlotinib Treatment Beyond Progression in EGFR Mutant Patients Who Have Responded to EGFR TKIs in Stage IIIB/IV NSCLC: An Open Label Randomized Trial
 Abstract  PDF  Full Text
Two Cases of Thoracic SMARCA4-Deficient Undifferentiated Tumor: A Case Report
 Abstract  PDF  Full Text
View More...